Do analysts recommend SBTX or ACHV?

Achieve Life Sciences has a consensus target price of $15.00, indicating a potential upside of 76.68%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Achieve Life Sciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, SBTX or ACHV?

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A

Is SBTX or ACHV more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Achieve Life Sciences N/A -511.12% -82.35%

Do analysts prefer GLAS or SBTX?

Glass House Brands currently has a consensus price target of $16.00, indicating a potential upside of 79.98%. Given Glass House Brands' stronger consensus rating and higher possible upside, research analysts clearly believe Glass House Brands is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Glass House Brands 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, GLAS or SBTX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A

Is GLAS or SBTX more profitable?

Glass House Brands' return on equity of 0.00% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Glass House Brands N/A N/A N/A Silverback Therapeutics N/A -29.62% -28.20%

Do analysts rate GYRE or SBTX?

Gyre Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 133.24%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 2 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.67 Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate SBTX or DRUG?

Bright Minds Biosciences has a consensus target price of $143.83, indicating a potential upside of 120.74%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Bright Minds Biosciences is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Bright Minds Biosciences 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00

Which has stronger valuation and earnings, SBTX or DRUG?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silverback Therapeutics N/A N/A -$89.48M -$2.42 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.08 N/A

Is SBTX or DRUG more profitable?

Bright Minds Biosciences' return on equity of -12.46% beat Silverback Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Bright Minds Biosciences N/A -12.46% -12.30%

Silverback Therapeutics (SBTX) Competitors

$5.62 -0.05 (-0.88%)

As of 09/4/2026

Compare

SBTX vs. COLL, ACHV, GLAS, GYRE, and DRUG

Should you buy Silverback Therapeutics stock or one of its competitors? Silverback Therapeutics's main competitors and comparable companies include Collegium Pharmaceutical (COLL), Achieve Life Sciences (ACHV), Glass House Brands (GLAS), Gyre Therapeutics (GYRE), and Bright Minds Biosciences (DRUG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Silverback Therapeutics compare to Collegium Pharmaceutical?

Collegium Pharmaceutical (NASDAQ:COLL) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Collegium Pharmaceutical has a net margin of 5.93% compared to Silverback Therapeutics' net margin of 0.00%. Collegium Pharmaceutical's return on equity of 91.43% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Collegium Pharmaceutical	5.93%	91.43%	15.57%
Silverback Therapeutics	N/A	-29.62%	-28.20%

Collegium Pharmaceutical has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Collegium Pharmaceutical	$780.57M	0.98	$62.87M	$1.24	18.98
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

74.9% of Silverback Therapeutics shares are owned by institutional investors. 1.9% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 34.4% of Silverback Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Collegium Pharmaceutical currently has a consensus price target of $51.00, suggesting a potential upside of 116.74%. Given Collegium Pharmaceutical's stronger consensus rating and higher probable upside, equities analysts clearly believe Collegium Pharmaceutical is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Collegium Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Collegium Pharmaceutical had 6 more articles in the media than Silverback Therapeutics. MarketBeat recorded 6 mentions for Collegium Pharmaceutical and 0 mentions for Silverback Therapeutics. Collegium Pharmaceutical's average media sentiment score of 1.06 beat Silverback Therapeutics' score of 0.00 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.

Company	Overall Sentiment
Collegium Pharmaceutical	Positive
Silverback Therapeutics	Neutral

Collegium Pharmaceutical has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Summary

Collegium Pharmaceutical beats Silverback Therapeutics on 14 of the 16 factors compared between the two stocks.

How does Silverback Therapeutics compare to Achieve Life Sciences?

Silverback Therapeutics (NASDAQ:SBTX) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

Achieve Life Sciences is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Silverback Therapeutics' return on equity of -29.62% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Achieve Life Sciences has a consensus target price of $15.00, indicating a potential upside of 76.68%. Given Achieve Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Silverback Therapeutics has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

In the previous week, Achieve Life Sciences had 9 more articles in the media than Silverback Therapeutics. MarketBeat recorded 9 mentions for Achieve Life Sciences and 0 mentions for Silverback Therapeutics. Achieve Life Sciences' average media sentiment score of 0.78 beat Silverback Therapeutics' score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Achieve Life Sciences	Positive

Summary

Achieve Life Sciences beats Silverback Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Silverback Therapeutics compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

74.9% of Silverback Therapeutics shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Glass House Brands' return on equity of 0.00% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Silverback Therapeutics	N/A	-29.62%	-28.20%

In the previous week, Glass House Brands had 4 more articles in the media than Silverback Therapeutics. MarketBeat recorded 4 mentions for Glass House Brands and 0 mentions for Silverback Therapeutics. Glass House Brands' average media sentiment score of 0.87 beat Silverback Therapeutics' score of 0.00 indicating that Glass House Brands is being referred to more favorably in the media.

Company	Overall Sentiment
Glass House Brands	Positive
Silverback Therapeutics	Neutral

Glass House Brands currently has a consensus price target of $16.00, indicating a potential upside of 79.98%. Given Glass House Brands' stronger consensus rating and higher possible upside, research analysts clearly believe Glass House Brands is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Glass House Brands beats Silverback Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Silverback Therapeutics compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Silverback Therapeutics (NASDAQ:SBTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Gyre Therapeutics presently has a consensus price target of $16.00, indicating a potential upside of 133.24%. Given Gyre Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Gyre Therapeutics is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Gyre Therapeutics had 2 more articles in the media than Silverback Therapeutics. MarketBeat recorded 2 mentions for Gyre Therapeutics and 0 mentions for Silverback Therapeutics. Gyre Therapeutics' average media sentiment score of 0.86 beat Silverback Therapeutics' score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gyre Therapeutics	Positive
Silverback Therapeutics	Neutral

Gyre Therapeutics has higher revenue and earnings than Silverback Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.56	$5.03M	-$0.21	N/A
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A

Gyre Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market.

Silverback Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Gyre Therapeutics' return on equity of -6.57% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Silverback Therapeutics	N/A	-29.62%	-28.20%

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 74.9% of Silverback Therapeutics shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 34.4% of Silverback Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Gyre Therapeutics beats Silverback Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Silverback Therapeutics compare to Bright Minds Biosciences?

Silverback Therapeutics (NASDAQ:SBTX) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Bright Minds Biosciences has a consensus target price of $143.83, indicating a potential upside of 120.74%. Given Bright Minds Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Bright Minds Biosciences is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by company insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bright Minds Biosciences' return on equity of -12.46% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Bright Minds Biosciences	N/A	-12.46%	-12.30%

In the previous week, Bright Minds Biosciences had 3 more articles in the media than Silverback Therapeutics. MarketBeat recorded 3 mentions for Bright Minds Biosciences and 0 mentions for Silverback Therapeutics. Bright Minds Biosciences' average media sentiment score of 0.70 beat Silverback Therapeutics' score of 0.00 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Bright Minds Biosciences	Positive

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.08	N/A

Silverback Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.36, meaning that its share price is 636% less volatile than the broader market.

Summary

Bright Minds Biosciences beats Silverback Therapeutics on 11 of the 14 factors compared between the two stocks.

Get Silverback Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SBTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SBTX vs. The Competition

Export

Metric	Silverback Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$202.65M	$12.19B	$7.21B	$12.89B
Dividend Yield	N/A	2.59%	2.54%	9.13%
P/E Ratio	-2.32	792.20	273.83	25.45
Price / Sales	N/A	757.13	622.29	101.10
Price / Cash	N/A	15.18	28.92	35.62
Price / Book	0.76	11.06	10.89	6.39
Net Income	-$89.48M	$2.83B	$3.49B	$358.69M
7 Day Performance	-4.58%	4.45%	1.64%	0.22%
1 Month Performance	1.26%	6.88%	4.43%	-0.10%
1 Year Performance	-44.19%	10.02%	24.21%	14.04%

Silverback Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SBTX Silverback Therapeutics	N/A	$5.62 -0.9%	N/A	-44.2%	$202.65M	N/A	N/A	83	High Trading Volume
COLL Collegium Pharmaceutical	2.9867 of 5 stars	$26.44 -3.9%	$51.00 +92.9%	-38.6%	$860.78M	$808.21M	21.32	210	Positive News Analyst Downgrade
ACHV Achieve Life Sciences	2.9699 of 5 stars	$8.18 -1.1%	$15.00 +83.4%	+200.0%	$841.72M	N/A	N/A	20	Positive News
GLAS Glass House Brands	3.1278 of 5 stars	$9.84 -5.4%	$16.00 +62.7%	N/A	$789.46M	N/A	N/A	N/A	Gap Down
GYRE Gyre Therapeutics	1.7812 of 5 stars	$6.68 +0.5%	$16.00 +139.5%	-10.8%	$744.89M	$116.59M	N/A	40	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SBTX) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Silverback Therapeutics (SBTX) Competitors

SBTX vs. COLL, ACHV, GLAS, GYRE, and DRUG

How does Silverback Therapeutics compare to Collegium Pharmaceutical?

Summary

How does Silverback Therapeutics compare to Achieve Life Sciences?

Summary

How does Silverback Therapeutics compare to Glass House Brands?

Summary

How does Silverback Therapeutics compare to Gyre Therapeutics?

Summary

How does Silverback Therapeutics compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Silverback Therapeutics (SBTX) Competitors

SBTX vs. COLL, ACHV, GLAS, GYRE, and DRUG

How does Silverback Therapeutics compare to Collegium Pharmaceutical?

Is COLL or SBTX more profitable?

Which has higher valuation & earnings, COLL or SBTX?

Do insiders and institutionals hold more shares of COLL or SBTX?

Do analysts prefer COLL or SBTX?

Does the media favor COLL or SBTX?

Which has more volatility & risk, COLL or SBTX?

Summary

How does Silverback Therapeutics compare to Achieve Life Sciences?

Which has higher earnings and valuation, SBTX or ACHV?

Do institutionals and insiders believe in SBTX or ACHV?

Is SBTX or ACHV more profitable?

Do analysts recommend SBTX or ACHV?

Which has more volatility & risk, SBTX or ACHV?

Does the media refer more to SBTX or ACHV?

Summary

How does Silverback Therapeutics compare to Glass House Brands?

Which has higher valuation & earnings, GLAS or SBTX?

Do institutionals & insiders believe in GLAS or SBTX?

Is GLAS or SBTX more profitable?

Does the media favor GLAS or SBTX?

Do analysts prefer GLAS or SBTX?

Summary

How does Silverback Therapeutics compare to Gyre Therapeutics?

Do analysts rate GYRE or SBTX?

Does the media favor GYRE or SBTX?

Which has preferable earnings and valuation, GYRE or SBTX?

Which has more risk and volatility, GYRE or SBTX?

Is GYRE or SBTX more profitable?

Do insiders & institutionals believe in GYRE or SBTX?

Summary

How does Silverback Therapeutics compare to Bright Minds Biosciences?

Do analysts rate SBTX or DRUG?

Do insiders and institutionals believe in SBTX or DRUG?

Is SBTX or DRUG more profitable?

Does the media refer more to SBTX or DRUG?

Which has stronger valuation and earnings, SBTX or DRUG?

Which has more volatility and risk, SBTX or DRUG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SBTX vs. The Competition

Silverback Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools